|
1.
|
|
18 p, 436.4 KB |
COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
/
Cross, Anne H. (Department of Neurology. Washington University) ;
Delgado, Silvia (University of Miami Miller School of Medicine) ;
Habek, Mario (University Hospital Center Zagreb. University of Zagreb. School of Medicine) ;
Davydovskaya, Maria (Moscow State Public Healthcare InsCity Clinical Hospital 24) ;
Ward, Brian J. (Infectious Diseases Division. Research Institute of the McGill University Health Centre) ;
Cree, Bruce A. C (UCSF Weill Institute for Neurosciences. Department of Neurology. University of California San Francisco) ;
Totolyan, Natalia (First Saint Petersburg State Medical University) ;
Pingili, Ratnakar (Novartis Pharmaceuticals Corporation) ;
Mancione, Linda (Novartis Pharmaceuticals Corporation) ;
Hu, Xixi (Novartis Pharmaceuticals Corporation) ;
Sullivan, Roseanne (Novartis Pharmaceuticals Corporation) ;
Su, Wendy (Novartis Pharmaceuticals Corporation) ;
Zielman, Ronald (Novartis Pharma B.V.) ;
Gupta, Ayan Das (Novartis Healthcare Private Limited) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron. Centre d'Esclerosi Mútiple de Catalunya) ;
Winthrop, Kevin (School of Public Health at Oregon Health and Science University) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Introduction: The SARS-CoV-2 pandemic necessitated better understanding of the impact of disease-modifying therapies on COVID-19 outcomes and vaccination. We report characteristics of COVID-19 cases and vaccination status in ofatumumab-treated relapsing multiple sclerosis (RMS) patients. [...]
2022 -  10.1007/s40120-022-00341-z
Neurology and Therapy, Vol. 11 Núm. 2 (june 2022) , p. 741-758
|
|
|
2.
|
|
9 p, 430.4 KB |
Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose
/
Domingo, Christian (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ;
Maspero, Jorge F (Fundación CIDEA) ;
Castro, Mario (University of Kansas School of Medicine) ;
Hanania, Nicola A. (Baylor College of Medicine) ;
Ford, Linda B (Asthma & Allergy Center) ;
Halpin, David M G (College of Medicine and Health) ;
Jackson, David J (King's College London) ;
Daizadeh, Nadia (Sanofi-Syntelabo) ;
Djandji, Michel (Sanofi-Syntelabo) ;
Mitchell, Colin P (Sanofi-Syntelabo) ;
Crikelair, Nora (Regeneron Pharmaceuticals. Inc) ;
Jacob-Nara, Juby A (Sanofi-Syntelabo) ;
Deniz, Yamo (Regeneron Pharmaceuticals. Inc) ;
Rowe, Paul J (Sanofi-Syntelabo) ;
Ortiz, Benjamin (Regeneron Pharmaceuticals. Inc) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Background: Dupilumab, a fully human monoclonal antibody, blocks the shared receptor component for interleukin-4/-13, key and central drivers of type 2 inflammation in multiple diseases. In the phase 3 LIBERTY ASTHMA VENTURE (VENTURE) study (NCT02528214), dupilumab versus placebo reduced oral corticosteroid (OCS) dose and improved clinical outcomes in patients with OCS-dependent severe asthma. [...]
2022 - 10.1016/j.jaip.2022.03.020
The Journal of allergy and clinical immunology. In practice, Vol. 10 Núm. 7 (July 2022) , p. 1835-1843
|
|
|
3.
|
|
4 p, 243.1 KB |
Correction to : COVID-19 Outcomes and Vaccination in People with Relapsing Multiple Sclerosis Treated with Ofatumumab
/
Cross, Anne H. (Department of Neurology. Washington University) ;
Delgado, Silvia (University of Miami Miller School of Medicine) ;
Habek, Mario (University Hospital Center Zagreb. University of Zagreb. School of Medicine) ;
Davydovskaya, Maria (Moscow State Public Healthcare InsCity Clinical Hospital 24) ;
Ward, Brian J. (Infectious Diseases Division. Research Institute of the McGill University Health Centre) ;
Cree, Bruce A. C (UCSF Weill Institute for Neurosciences. Department of Neurology. University of California San Francisco) ;
Totolyan, Natalia (First Saint Petersburg State Medical University) ;
Pingili, Ratnakar (Novartis Pharmaceuticals Corporation) ;
Mancione, Linda (Novartis Pharmaceuticals Corporation) ;
Hu, Xixi (Novartis Pharmaceuticals Corporation) ;
Sullivan, Roseanne (Novartis Pharmaceuticals Corporation) ;
Su, Wendy (Novartis Pharmaceuticals Corporation) ;
Zielman, Ronald (Novartis Pharma B.V.) ;
Gupta, Ayan Das (Novartis Healthcare Private Limited) ;
Montalban, Xavier (Hospital Universitari Vall d'Hebron. Centre d'Esclerosi Mútiple de Catalunya) ;
Winthrop, Kevin (School of Public Health at Oregon Health and Science University) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
2022 - 10.1007/s40120-022-00346-8
Neurology and Therapy, Vol. 11 Núm. 2 (2022) , p. 759-762
|
|
|
4.
|
|
11 p, 299.2 KB |
Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes : A prospective study of HIV-positive individuals
/
Cain, Lauren E. (Harvard T.H. Chan School of Public Health (Boston, Estats Units d'Amèrica)) ;
Caniglia, Ellen C. (Harvard T.H. Chan School of Public Health (Boston, Estats Units d'Amèrica)) ;
Phillips, Andrew (University College London) ;
Olson, Ashley ;
Muga, Roberto (Institut Germans Trias i Pujol) ;
Pérez Hoyos, Santiago ;
Abgrall, Sophie ;
Costagliola, Dominique ;
Rubio, Rafael ;
Jarrín, Inma ;
Bucher, Heiner ;
Fehr, Jan ;
van Sighem, Ard ;
Reiss, Peter ;
Dabis, François ;
Vandenhende, Marie-Anne ;
Logan, Roger ;
Robins, James ;
Sterne, Jonathan A C ;
Justice, Amy ;
Tate, Janet ;
Touloumi, Giota ;
Paparizos, Vasilis ;
Esteve, Anna ;
Casabona-Barbarà, Jordi ;
Seng, Rémonie ;
Meyer, Laurence ;
Jose, Sophie ;
Sabin, Caroline A ;
Hernán, Miguel A ;
HIV CAUSAL Collaboration ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Objective: To compare regimens consisting of either ritonavir-boosted atazanavir or efavirenz and a nucleoside reverse transcriptase inhibitor (NRTI) backbone with respect to clinical, immunologic, and virologic outcomes. [...]
2016 - 10.1097/MD.0000000000005133
Medicine, Vol. 95 Núm. 41 (2016) , art. e5133
|
|
|
5.
|
|
10 p, 1.1 MB |
Specific Plasma MicroRNA Signatures Underlying the Clinical Outcomes of Hepatitis E Virus Infection
/
Costafreda Salvany, Maria Isabel (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Sauleda, Silvia (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Riveiro Barciela, Mar (Hospital Universitari Vall d'Hebron) ;
Rico, Angie (Banc de Sang i Teixits de Catalunya) ;
Llorens-Revull, Meritxell (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Guix, Susana (Universitat de Barcelona) ;
Pintó, Rosa M. (Universitat de Barcelona) ;
Bosch, Albert (Universitat de Barcelona) ;
Rodriguez-Frias, Francisco (Hospital Universitari Vall d'Hebron) ;
Rando-Segura, Ariadna (Hospital Universitari Vall d'Hebron) ;
Piron, Maria (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Bes, Marta (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
The pathogenic mechanisms determining the diverse clinical outcomes of HEV infection (e. g. , self-limiting versus chronic or symptomatic versus asymptomatic) are not yet understood. Because specific microRNA signatures during viral infection inform the cellular processes involved in virus replication and pathogenesis, we investigated plasma microRNA profiles in 44 subjects, including patients with symptomatic acute (AHE, n = 7) and chronic (CHE, n = 6) hepatitis E, blood donors with asymptomatic infection (HEV BDs, n = 9), and anti-HEV IgG + IgM − (exposed BDs, n = 10) and anti-HEV IgG − IgM − (naive BDs, n = 12) healthy blood donors. [...]
2023 - 10.1128/spectrum.04664-22
Microbiology Spectrum, Vol. 11 (january 2023)
|
|
|
6.
|
|
11 p, 973.1 KB |
Strategies to reengage patients lost to follow up in HIV care in high income countries, a scoping review
/
Palacio-Vieira, Jorge (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Reyes-Urueña, Juliana (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Imaz, Arkaitz (Hospital Universitari de Bellvitge) ;
Bruguera, Andreu (Institut Germans Trias i Pujol) ;
Force, Lluís (Hospital de Mataró. Consorci Sanitari del Maresme) ;
Orti Llaveria, Amat (Hospital de Tortosa Verge de la Cinta) ;
Llibre, Josep M. (Institut Germans Trias i Pujol. Fundació de Lluita Contra la Sida) ;
Vilaró, Ingrid (Hospital General de Vic) ;
Homar Borràs, Francesc (Hospital Universitari Son Llàtzer (Palma de Mallorca, Balears)) ;
Falcó, Vicenç (Hospital Universitari Vall d'Hebron. Institut de Recerca) ;
Riera, Melchor (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Domingo, Pere (Institut d'Investigació Biomèdica Sant Pau) ;
de Lazzari, Elisa (Hospital Clínic i Provincial de Barcelona) ;
Miró, Josep M. (Hospital Clínic i Provincial de Barcelona) ;
Casabona-Barbarà, Jordi (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Background: Despite remarkable achievements in antiretroviral therapy (ART), losses to follow-up (LTFU) might prevent the long-term success of HIV treatment and might delay the achievement of the 90-90-90 objectives. [...]
2021 - 10.1186/s12889-021-11613-y
BMC public health, Vol. 21 Núm. 1 (december 2021) , p. 1596
|
|
|
7.
|
|
16 p, 1.7 MB |
Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies : The GETH/GELTAMO Experience
/
Gutiérrez, Antonio (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Bento, Leyre (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Novelli, Silvana (Hospital Sant Creu i Sant Pau. Service of Hematology) ;
Martin, Alejandro (Hospital Universitario de Salamanca) ;
Gutierrez, Gonzalo (Hospital Clínic i Provincial de Barcelona) ;
Salas, Maria Queralt (Hospital Clínic i Provincial de Barcelona) ;
Bastos-Oreiro, Mariana (Hospital General Universitario Gregorio Marañón) ;
Perez, Ariadna (Hospital Clínic Universitari (València)) ;
Hernani, Rafael (Hospital Clínic Universitari (València)) ;
Viguria, Maria Cruz (Complejo Hospitalario de Navarra) ;
Lopez-Godino, Oriana (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Montoro, Juan (Hospital Universitari i Politècnic La Fe de València) ;
Piñana, José Luis (Hospital Universitari i Politècnic La Fe de València) ;
Ferrá, Christelle (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Parody, Rocio (Institut Català d'Oncologia) ;
Martin, Carmen (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Español, Ignacio (Hospital Universitario Virgen de la Arrixaca (Múrcia)) ;
Yañez, Lucrecia (Instituto de Investigación Marqués de Valdecilla) ;
Rodriguez, Guillermo (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Zanabili, Joud (Hospital Asturias) ;
Herrera, Pilar (Hospital Universitario Ramón y Cajal (Madrid)) ;
Varela, Maria Rosario (Complejo Hospital Juan Canalejo) ;
Sampol, Antonia (Hospital Universitari Son Espases (Palma de Mallorca, Balears)) ;
Solano, Carlos (Hospital Clínic Universitari (València)) ;
Caballero, Dolores (Hospital Universitario de Salamanca) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Allo-SCT is a curative option for selected patients with relapsed/refractory (R/R) MCL, but with significant NRM. We present the long-term results of patients receiving allo-SCT in Spain from March 1995 to February 2020. [...]
2022 - 10.3390/cancers14112673
Cancers, Vol. 14 Núm. 11 (6-1 2022) , p. 2673
|
|
|
8.
|
|
|
9.
|
|
8 p, 440.5 KB |
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation : A Report on Behalf of the American Society for Transplantation and Cellular Therapy
/
Kharfan-Dabaja, Mohamed A. (Mayo Clinic. Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapies Program) ;
Kumar, Ambuj (Program for Comparative Effectiveness Research. Morsani College of Medicine. University of South Florida) ;
Ayala, Ernesto (Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapies Program. Mayo Clinic) ;
Aljurf, Mahmoud (Department of Adult Hematology and Stem Cell Transplantation. King Faisal Specialist Hospital and Research Centre) ;
Nishihori, Taiga (Department of Blood and Marrow Transplantation and Cellular Immunotherapy. Moffitt Cancer Center) ;
Marsh, Rebecca (Cincinnati Children's Hospital Medical Center) ;
Burroughs, Laura M. (Fred Hutchinson Cancer Research Center) ;
Majhail, Navneet (Blood and Marrow Transplant Program. Taussig Cancer Institute. Cleveland Clinic) ;
Al-Homsi, Ahmad Samer (NYU Langone Health) ;
Al-Kadhimi, Zaid S. (Division of Oncology and Hematology. Department of Internal Medicine. University of Nebraska Medical Center) ;
Bar, Merav (Fred Hutchinson Cancer Research Center) ;
Bertaina, Alice (Division of Stem Cell Transplant and Regenerative Medicine. Department of Pediatrics. Stanford University) ;
Boelens, Jaap Jan (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ;
Champlin, Richard (Department of Stem Cell Transplantation and Cellular Therapy. The University of Texas MD Anderson Cancer Center) ;
Chaudhury, Sonali (Ann and Robert H. Lurie Children's Hospital of Chicago) ;
DeFilipp, Zachariah (Department of Hematology-Oncology and Hematopoietic Cell Transplant and Cellular Therapy Program. Massachusetts General Hospital) ;
Dholaria, Bhagirathbhai (Vanderbilt University Medical Center) ;
El-Jawahri, Areej (Department of Hematology-Oncology and Hematopoietic Cell Transplant and Cellular Therapy Program. Massachusetts General Hospital) ;
Fanning, Suzanne (Blood and Marrow Transplant Program. University of South Carolina School of Medicine) ;
Fraint, Ellen (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ;
Gergis, Usama (Bone Marrow Transplant and Immune Cellular Therapy. Thomas Jefferson University Hospital) ;
Giralt, Sergio (Department of Medicine. Division of Hematologic Malignancies. Memorial Sloan Kettering Cancer Center Weill Cornell Medical College) ;
Hamilton, Betty K. (Blood and Marrow Transplant Program. Taussig Cancer Institute. Cleveland Clinic) ;
Hashmi, Shahrukh K (Department of Medicine. Sheikh Shakhbout Medical City) ;
Horn, Biljana (Department of Pediatrics. Division of Hematology/Oncology. University of Florida. UF Health Shands Children's Hospital) ;
Inamoto, Yoshihiro (Department of Hematopoietic Stem Cell Transplantation. National Cancer Center Hospital) ;
Jacobsohn, David A. (Division of Blood and Marrow Transplantation Center for Cancer and Blood Disorders. Children's National Medical Center) ;
Jain, Tania (Hematologic Malignancies and Bone Marrow Transplantation Program. Sidney Kimmel Comprehensive Cancer Center. Johns Hopkins University School of Medicine) ;
Johnston, Laura (Division of Blood and Marrow Transplantation. Department of Medicine. Stanford University School of Medicine) ;
Kanate, Abraham S. (West Virginia University) ;
Kansagra, Ankit (UT Southwestern Medical Center) ;
Kassim, Adetola (Department of Hematology-Oncology. Vanderbilt University Medical Center) ;
Kean, Leslie S. (Boston Children's Hospital. Dana-Farber Cancer Institute) ;
Kitko, Carrie L. (Division of Pediatric Hematology/Oncology. Department of Pediatrics. Vanderbilt University Medical Center) ;
Knight-Perry, Jessica (Department of Pediatrics. Division of Hematology/Oncology/BMT. University of Colorado School of Medicine) ;
Kurtzberg, Joanne (Pediatric Blood and Marrow Transplant Program. Duke University School of Medicine) ;
Liu, Hien (Department of Blood and Marrow Transplantation and Cellular Immunotherapy. Moffitt Cancer Center) ;
MacMillan, Margaret L (Blood and Marrow Transplant Program. Masonic Cancer Center. University of Minnesota Medical School) ;
Mahmoudjafari, Zahra (Division of Pharmacy. University of Kansas Cancer Center. University of Kansas Health System) ;
Mielcarek, Marco (Fred Hutchinson Cancer Research Center) ;
Mohty, Mohamad (Sorbonne Université. INSERM. Centre de Recherche Saint-Antoine and Hôpital Saint-Antoine. Service d'Hématologie Clinique et Thérapie Cellulaire) ;
Nagler, Arnon (Chaim Sheba Medical Center (Israel)) ;
Nemecek, Eneida (Knight Cancer Institute. Oregon Health & Science University) ;
Olson, Timothy S. (Blood and Marrow Transplant Section. Division of Oncology. Department of Pediatrics. Children's Hospital of Philadelphia) ;
Oran, Betul (Department of Stem Cell Transplantation and Cellular Therapy. The University of Texas MD Anderson Cancer Center) ;
Perales, Miguel Angel (Department of Medicine. Division of Hematologic Malignancies. Memorial Sloan Kettering Cancer Center Weill Cornell Medical College) ;
Prockop, Susan E. (Stem Cell Transplantation and Cellular Therapies Program. Department Pediatrics. Memorial Sloan Kettering Cancer Center) ;
Pulsipher, Michael A. (Children's Hospital Los Angeles Cancer and Blood Disease Institute. USC Keck School of Medicine) ;
Pusic, Iskra (Division of Oncology. Department of Medicine. Washington University School of Medicine) ;
Riches, Marcie L. (Division of Hematology. University of North Carolina at Chapel Hill) ;
Rodriguez, Cesar (Department of Hematology and Oncology. Wake Forest University School of Medicine) ;
Romee, Rizwan (Cellular Therapy and Stem Cell Transplant Program. Dana Farber Cancer Institute. Harvard Medical School) ;
Rondon, Gabriela (The University of Texas MD Anderson Cancer Center) ;
Saad, Ayman (The Ohio State University. Division of Hematology) ;
Shah, Nina (University of California San Francisco. Department of Medicine) ;
Shaw, Peter J. (The Children's Hospital at Westmead) ;
Shenoy, Shalini (Washington University School of Medicine) ;
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau) ;
Talano, Julie (Children's Hospital of Wisconsin) ;
Verneris, Michael R. (University of Colorado School of Medicine) ;
Veys, Paul (University College London. Great Ormond Street Hospital.) ;
Wagner, John E. (University of Minnesota Medical School) ;
Savani, Bipin N. (Vanderbilt University Medical Center) ;
Hamadani, Mehdi (Medical College of Wisconsin) ;
Carpenter, Paul A. (Fred Hutchinson Cancer Research Center) ;
Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras ;
Universitat Autònoma de Barcelona.
Departament de Medicina
Allogeneic hematopoietic cell transplantation (allo-HCT) is potentially curative for certain hematologic malignancies and nonmalignant diseases. The field of allo-HCT has witnessed significant advances, including broadening indications for transplantation, availability of alternative donor sources, less toxic preparative regimens, new cell manipulation techniques, and novel GVHD prevention methods, all of which have expanded the applicability of the procedure. [...]
2021 - 10.1016/j.jtct.2021.04.007
Transplantation and Cellular Therapy, Vol. 27 Núm. 8 (august 2021) , p. 642-649
|
|
|
10.
|
|
15 p, 1.0 MB |
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia
/
Martínez-Cuadrón, David (Hospital Universitari i Politècnic La Fe de València) ;
Serrano, J. (Hospital Universitario Reina Sofía and Instituto Maimónides de Investigación Biomédica Córdoba) ;
Mariz, José (Istituto Portugues Oncologia) ;
Gil, C. (Hospital General Universitario de Alicante (Alacant)) ;
Tormo, M. (Hospital Clínic Universitari (València)) ;
Martínez-Sánchez, P. (Hospital Universitario 12 de Octubre (Madrid)) ;
Rodríguez-Arbolí, Eduardo (Hospital Universitario Virgen del Rocío) ;
García-Boyero, R. (Hospital General Universitari de Castelló) ;
Rodríguez-Medina, C. (Hospital Universitario de Gran Canaria Dr. Negrín) ;
Martínez-Chamorro, C. (Hospital Quirón Pozuelo) ;
Polo, M. (Hospital Clínico San Carlos (Madrid)) ;
Bergua Burgues, Juan Miguel (Hospital San Pedro Alcántara) ;
Aguiar, Eliana (Hospital Sao Joao) ;
Amigo, María-Luz (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Herrera, P. (Hospital Universitario Ramón y Cajal (Madrid)) ;
Alonso-Domínguez, Juan Manuel (Hospital Universitario Fundación Jiménez Díaz) ;
Bernal, Teresa (Hospital Universitario Central de Asturias) ;
Espadana, A. (Hospital de Coimbra) ;
Sayas, M.J. (Hospital Universitari Doctor Peset (València)) ;
Algarra, Lorenzo (Complejo Hospitalario Universitario de Albacete) ;
Vidriales, M.B. (Instituto de Investigación Biomédica de Salamanca) ;
Vasconcelos, G. (Hospital de Santa Maria) ;
Vives Polo, Susana (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Pérez-Encinas, M.M. (Hospital Clínico Universitario (Galícia)) ;
López, A. (Hospital Arnau de Vilanova (València)) ;
Noriega, V. (Complejo Hospitalario Universitario de A Coruña) ;
García-Fortes, M. (Hospital Universitario Virgen de la Victoria) ;
Chillón, M. Carmen (Centro de Investigación Biomédica en Red de Cáncer) ;
Rodríguez-Gutiérrez, J.I. (Hospital de Basurto (Bilbao, Biscaia)) ;
Calasanz, M.J (Clínica Universidad de Navarra) ;
Labrador, Jorge (Hospital Universitario de Burgos) ;
López, J. A. (Complejo Hospitalario Ciudad de Jaén) ;
Boluda, Blanca (Hospital Universitari i Politècnic La Fe de València) ;
Rodríguez-Veiga, R. (Hospital Universitari i Politècnic La Fe de València) ;
Martínez-López, J. (Hospital Universitario 12 de Octubre) ;
Barragán, Eva (Hospital Universitari i Politècnic La Fe de València) ;
Sanz, Miguel A. (Hospital Universitari i Politècnic La Fe de València) ;
Montesinos, P. (Hospital Universitari i Politècnic La Fe de València) ;
Universitat Autònoma de Barcelona.
Departament de Medicina
This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. [...]
2022 - 10.3390/cancers14112817
Cancers, Vol. 14 Núm. 11 (6-1 2022) , p. 2817
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
